Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioblastoma 3Virus Diseases 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Melanoma 1Lung Neoplasms 1Head and Neck Neoplasms 1Glioma 1CRC 1Breast Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 109Magnetic Resonance Spectroscopy 52Bevacizumab 52Radiotherapy 44Irinotecan 27Blood Specimen Collection 19Surgical Procedures, Operative 16Radiation 15Aminolevulinic Acid 15Carboplatin 13fluorodopa F 18 12Nivolumab 12Radiotherapy, Intensity-Modulated 11Carmustine 11Radiosurgery 10Magnetic Resonance Imaging 10pembrolizumab 9Topotecan 9Specimen Handling 9Everolimus 9Erlotinib Hydrochloride 9Biopsy 9poly ICLC 8Surveys and Questionnaires 8Standard of Care 8Etoposide 8Drug Therapy 8Lomustine 7Filgrastim 7Cyclophosphamide 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Glioma × Oncolytic Virotherapy × Clear all
NCT06562621 2024-08-20

Clinical Study on the Safety and Efficacy of Novel Oncolytic Virus in the Treatment of Recurrent Malignant Glioma

Beijing Neurosurgical Institute

Phase 1/2 Completed
38 enrolled
CNS

Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡